{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T14:45:30Z","timestamp":1791297930800,"version":"4.1.0"},"reference-count":174,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2014,5,1]],"date-time":"2014-05-01T00:00:00Z","timestamp":1398902400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,5,19]],"date-time":"2014-05-19T00:00:00Z","timestamp":1400457600000},"content-version":"vor","delay-in-days":18,"URL":"http:\/\/creativecommons.org\/licenses\/by\/3.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Antiviral Research"],"published-print":{"date-parts":[[2014,5]]},"DOI":"10.1016\/j.antiviral.2014.02.013","type":"journal-article","created":{"date-parts":[[2014,2,25]],"date-time":"2014-02-25T23:19:59Z","timestamp":1393370399000},"page":"100-111","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":127,"special_numbering":"C","title":["The past, present and future of neutralizing antibodies for hepatitis C virus"],"prefix":"10.1016","volume":"105","author":[{"given":"Jonathan K.","family":"Ball","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander W.","family":"Tarr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane A.","family":"McKeating","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.antiviral.2014.02.013_b0005","doi-asserted-by":"crossref","first-page":"9605","DOI":"10.1128\/JVI.78.18.9605-9611.2004","article-title":"Effect of the addition of oligosaccharides on the biological activities and antigenicity of influenza A\/H3N2 virus hemagglutinin","volume":"78","author":"Abe","year":"2004","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2014.02.013_b0010","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1099\/vir.2008.006049-0","article-title":"Expression of hepatitis C virus (HCV) structural proteins in trans facilitates encapsidation and transmission of HCV subgenomic RNA","volume":"90","author":"Adair","year":"2009","journal-title":"J. Gen. Virol."},{"key":"10.1016\/j.antiviral.2014.02.013_b0015","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1016\/j.vaccine.2011.11.089","article-title":"An engineered mutant of HIV-1 gp120 formulated with adjuvant Quil A promotes elicitation of antibody responses overlapping the CD4-binding site","volume":"30","author":"Ahmed","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.antiviral.2014.02.013_b0020","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1002\/hep.22534","article-title":"High incidence of hepatitis C virus reinfection in a cohort of injecting drug users","volume":"48","author":"Aitken","year":"2008","journal-title":"Hepatology"},{"issue":"447\u2013455","key":"10.1016\/j.antiviral.2014.02.013_b0025","first-page":"e441","article-title":"Neutralizing antibodies induced by cell culture-derived hepatitis C virus protect against infection in mice","volume":"145","author":"Akazawa","year":"2013","journal-title":"Gastroenterology"},{"key":"10.1016\/j.antiviral.2014.02.013_b0030","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1093\/infdis\/175.1.26","article-title":"Patients infected with the same hepatitis C virus strain display different kinetics of the isolate-specific antibody response","volume":"175","author":"Allander","year":"1997","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.antiviral.2014.02.013_b0035","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1002\/hep.24686","article-title":"CD59 incorporation protects hepatitis C virus against complement-mediated destruction","volume":"55","author":"Amet","year":"2012","journal-title":"Hepatology"},{"key":"10.1016\/j.antiviral.2014.02.013_b0040","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1093\/infdis\/jit376","article-title":"Additional glycosylation within a specific hypervariable region of subtype 3a of hepatitis C virus protects against virus neutralization","volume":"208","author":"Anjum","year":"2013","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.antiviral.2014.02.013_b0045","doi-asserted-by":"crossref","first-page":"4157","DOI":"10.1128\/JVI.02449-10","article-title":"Transcriptional repression of C4 complement by hepatitis C virus proteins","volume":"85","author":"Banerjee","year":"2011","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2014.02.013_b0050","doi-asserted-by":"crossref","first-page":"5751","DOI":"10.1128\/JVI.02200-09","article-title":"Hepatitis C virus hypervariable region 1 modulates receptor interactions, conceals the CD81 binding site, and protects conserved neutralizing epitopes","volume":"84","author":"Bankwitz","year":"2010","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2014.02.013_b0930","doi-asserted-by":"crossref","first-page":"115ra111","DOI":"10.1126\/scitranslmed.3003155","article-title":"Novel adenovirus-based vaccines induce broad and sustained T cell responses to HCV in man","volume":"4","author":"Barnes","year":"2012","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.antiviral.2014.02.013_b0060","doi-asserted-by":"crossref","first-page":"14199","DOI":"10.1073\/pnas.2335981100","article-title":"In vitro assay for neutralizing antibody to hepatitis C virus: evidence for broadly conserved neutralization epitopes","volume":"100","author":"Bartosch","year":"2003","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.antiviral.2014.02.013_b0065","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1084\/jem.20021756","article-title":"Infectious hepatitis C virus pseudo-particles containing functional E1\u2013E2 envelope protein complexes","volume":"197","author":"Bartosch","year":"2003","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.antiviral.2014.02.013_b0070","doi-asserted-by":"crossref","first-page":"41624","DOI":"10.1074\/jbc.M305289200","article-title":"Cell entry of hepatitis C virus requires a set of co-receptors that include the CD81 tetraspanin and the SR-B1 scavenger receptor","volume":"278","author":"Bartosch","year":"2003","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.antiviral.2014.02.013_b0075","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1053\/jhep.2001.24371","article-title":"Protective immune response to hepatitis C virus in chimpanzees rechallenged following clearance of primary infection","volume":"33","author":"Bassett","year":"2001","journal-title":"Hepatology"},{"key":"10.1016\/j.antiviral.2014.02.013_b0080","doi-asserted-by":"crossref","first-page":"3827","DOI":"10.1128\/JVI.72.5.3827-3836.1998","article-title":"Hepatitis C virus structural proteins assemble into viruslike particles in insect cells","volume":"72","author":"Baumert","year":"1998","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2014.02.013_b0880","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1053\/jhep.2000.9876","article-title":"Antibodies against hepatitis C virus-like particles and viral clearance in acute and chronic hepatitis C","volume":"32","author":"Baumert","year":"2000","journal-title":"Hepatology"},{"key":"10.1016\/j.antiviral.2014.02.013_b0090","first-page":"49","article-title":"Animal models for hepatitis C","volume":"369","author":"Billerbeck","year":"2013","journal-title":"Curr. Top. Microbiol. Immunol."},{"key":"10.1016\/j.antiviral.2014.02.013_b0095","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1056\/NEJM199412153312402","article-title":"Hepatitis C infection in patients with primary hypogammaglobulinaemia after treatment with contaminated immune globulin","volume":"331","author":"Bjoro","year":"1994","journal-title":"New Engl. J. Med."},{"key":"10.1016\/j.antiviral.2014.02.013_b0100","doi-asserted-by":"crossref","first-page":"6964","DOI":"10.1128\/JVI.00024-06","article-title":"Hepatitis C virus entry depends on clathrin-mediated endocytosis","volume":"80","author":"Blanchard","year":"2006","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2014.02.013_b0105","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1002\/hep.510270134","article-title":"Comparison of the rate of sequence variation in the hypervariable region of E2\/NS1 region of hepatitis C virus in normal and hypogammaglobulinemic patients","volume":"27","author":"Booth","year":"1998","journal-title":"Hepatology"},{"key":"10.1016\/j.antiviral.2014.02.013_b0110","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1128\/JVI.01592-10","article-title":"Neutralising antibody-resistant hepatitis C virus cell-to-cell transmission","volume":"85","author":"Brimacombe","year":"2011","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2014.02.013_b0115","doi-asserted-by":"crossref","first-page":"12473","DOI":"10.1128\/JVI.01138-09","article-title":"Identification and characterization of broadly neutralizing human monoclonal antibodies directed against the E2 envelope glycoprotein of hepatitis C virus","volume":"83","author":"Broering","year":"2009","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2014.02.013_b0120","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1099\/vir.0.80957-0","article-title":"Evolutionary dynamics of hepatitis C virus envelope genes during chronic infection","volume":"86","author":"Brown","year":"2005","journal-title":"J. Gen. Virol."},{"key":"10.1016\/j.antiviral.2014.02.013_b0125","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1099\/vir.0.82357-0","article-title":"Cross-genotype characterization of genetic diversity and molecular adaptation in hepatitis C virus envelope glycoprotein genes","volume":"88","author":"Brown","year":"2007","journal-title":"J. Gen. Virol."},{"key":"10.1016\/j.antiviral.2014.02.013_b0130","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1038\/nri891","article-title":"Antibodies, viruses and vaccines","volume":"2","author":"Burton","year":"2002","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.antiviral.2014.02.013_b0135","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/S0016-5085(99)70237-4","article-title":"Limited humoral immunity in hepatitis C virus infection","volume":"116","author":"Chen","year":"1999","journal-title":"Gastroenterology"},{"key":"10.1016\/j.antiviral.2014.02.013_b0140","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1073\/pnas.91.4.1294","article-title":"Vaccination of chimpanzees against infection by the hepatitis C virus","volume":"91","author":"Choo","year":"1994","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.antiviral.2014.02.013_b0885","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1111\/ajt.12083","article-title":"Human monoclonal antibody MBL-HCV1 delays HCV viral rebound following liver transplantation: a randomized control study","volume":"13","author":"Chung","year":"2013","journal-title":"Am. J. Transplant."},{"key":"10.1016\/j.antiviral.2014.02.013_b0150","doi-asserted-by":"crossref","first-page":"7672","DOI":"10.1128\/JVI.76.15.7672-7682.2002","article-title":"Analysis of the antigenicity and topology of E2 glycoprotein present on the recombinant hepatitis C virus-like particles","volume":"76","author":"Clayton","year":"2002","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2014.02.013_b0155","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1126\/science.1205669","article-title":"A neutralizing antibody selected from plasma cells that binds to group 1 and group 2 influenza A hemagglutinins","volume":"333","author":"Corti","year":"2011","journal-title":"Science"},{"key":"10.1016\/j.antiviral.2014.02.013_b0890","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1002\/lt.20405","article-title":"A randomized, open-label study to evaluate the safety and pharmacokinetics of human hepatitis C immune globulin (Civacir) in liver transplant recipients","volume":"11","author":"Davis","year":"2005","journal-title":"Liver Transpl."},{"key":"10.1016\/j.antiviral.2014.02.013_b0165","doi-asserted-by":"crossref","first-page":"7418","DOI":"10.1073\/pnas.1305306110","article-title":"Structural evidence for a bifurcated mode of action in the antibody-mediated neutralization of hepatitis C virus","volume":"110","author":"Deng","year":"2013","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.antiviral.2014.02.013_b0170","doi-asserted-by":"crossref","first-page":"5494","DOI":"10.1128\/JVI.02153-09","article-title":"Mutations within a conserved region of the Hepatitis C virus E2 glycoprotein that influence virus-receptor interactions and sensitivity to neutralizing antibodies","volume":"84","author":"Dhillon","year":"2010","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2014.02.013_b0180","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1038\/nature10168","article-title":"A genetically humanized mouse model for hepatitis C virus infection","volume":"474","author":"Dorner","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.antiviral.2014.02.013_b0175","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1038\/nature12427","article-title":"Completion of the entire hepatitis C virus life cycle in genetically humanized mice","volume":"501","author":"Dorner","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.antiviral.2014.02.013_b0185","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.1053\/j.gastro.2009.02.080","article-title":"Selection pressure from neutralizing antibodies drives sequence evolution during acute infection with hepatitis C virus","volume":"136","author":"Dowd","year":"2009","journal-title":"Gastroenterology"},{"key":"10.1016\/j.antiviral.2014.02.013_b0190","doi-asserted-by":"crossref","first-page":"7844","DOI":"10.1128\/JVI.00029-06","article-title":"A conserved Gly(436)-Trp-Leu-Ala-Gly-Leu-Phe-Tyr motif in hepatitis C virus glycoprotein E2 is a determinant of CD81 binding and viral entry","volume":"80","author":"Drummer","year":"2006","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2014.02.013_b0195","doi-asserted-by":"crossref","first-page":"12686","DOI":"10.1128\/JVI.00994-12","article-title":"Amino acid residue-specific neutralization and nonneutralization of hepatitis C virus by monoclonal antibodies to the E2 protein","volume":"86","author":"Duan","year":"2012","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2014.02.013_b0200","doi-asserted-by":"crossref","first-page":"6147","DOI":"10.1128\/JVI.68.10.6147-6160.1994","article-title":"Formation and intracellular localisation of hepatitis C virus envelope glycoprotein complexes expressed by recombinant vaccinia and Sindbis viruses","volume":"68","author":"Dubuisson","year":"1994","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2014.02.013_b0895","doi-asserted-by":"crossref","first-page":"e45770","DOI":"10.1371\/journal.pone.0045770","article-title":"Specific acquisition of functional CD59 but not CD46 or CD55 by hepatitis C virus","volume":"7","author":"Ejaz","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.antiviral.2014.02.013_b0210","doi-asserted-by":"crossref","first-page":"8427","DOI":"10.1073\/pnas.0702162104","article-title":"Immunization with hepatitis C virus-like particles results in control of hepatitis C virus infection in chimpanzees","volume":"104","author":"Elmowalid","year":"2007","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.antiviral.2014.02.013_b0215","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1002\/ajh.21022","article-title":"Monitoring serum hepatitis C virus (HCV) RNA in patients with HCV-infected CD20-positive B-cell lymphoma undergoing rituximab combination chemotherapy","volume":"83","author":"Ennishi","year":"2008","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.antiviral.2014.02.013_b0220","doi-asserted-by":"crossref","first-page":"2654","DOI":"10.1128\/JVI.80.6.2654-2664.2006","article-title":"Preclinical evaluation of two neutralizing human monoclonal antibodies against hepatitis C virus (HCV): a potential treatment to prevent HCV reinfection in liver transplant patients","volume":"80","author":"Eren","year":"2006","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2014.02.013_b0230","doi-asserted-by":"crossref","first-page":"8072","DOI":"10.1128\/JVI.00459-07","article-title":"Hepatitis C virus envelope glycoprotein E2 glycans modulate entry, CD81 binding and neutralisation","volume":"81","author":"Falkowska","year":"2007","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2014.02.013_b0235","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1093\/infdis\/165.6.1006","article-title":"The natural history of infection with hepatitis C virus (HCV) in chimpanzees: comparison of serologic responses measured with first- and second-generation assays and relationship to HCV viremia","volume":"165","author":"Farci","year":"1992","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.antiviral.2014.02.013_b0245","doi-asserted-by":"crossref","first-page":"15394","DOI":"10.1073\/pnas.93.26.15394","article-title":"Prevention of hepatitis C virus infection in chimpanzees by hyperimmune serum against the hypervariable region 1 of the envelope 2 protein","volume":"93","author":"Farci","year":"1996","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.antiviral.2014.02.013_b0240","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1126\/science.288.5464.339","article-title":"The outcome of acute hepatitis C predicted by the evolution of the viral quasispecies","volume":"288","author":"Farci","year":"2000","journal-title":"Science"},{"key":"10.1016\/j.antiviral.2014.02.013_b0250","doi-asserted-by":"crossref","first-page":"810","DOI":"10.7326\/0003-4819-128-10-199805150-00003","article-title":"Incidence of hepatitis C in patients receiving different preparations of hepatitis B immunoglobulins after liver transplantation","volume":"128","author":"Feray","year":"1998","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.antiviral.2014.02.013_b0260","doi-asserted-by":"crossref","first-page":"6235","DOI":"10.1128\/JVI.73.8.6235-6244.1999","article-title":"Characterisation of hepatitis C virus E2 glycoprotein interaction with a putative cellular receptor, CD81","volume":"73","author":"Flint","year":"1999","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2014.02.013_b0265","doi-asserted-by":"crossref","first-page":"6782","DOI":"10.1128\/JVI.73.8.6782-6790.1999","article-title":"Functional analysis of cell surface-expressed hepatitis C virus E2 glycoprotein","volume":"73","author":"Flint","year":"1999","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2014.02.013_b0255","doi-asserted-by":"crossref","first-page":"6875","DOI":"10.1128\/JVI.78.13.6875-6882.2004","article-title":"Characterisation of infectious retroviral pseudotype particles bearing hepatitis C virus glycoproteins","volume":"78","author":"Flint","year":"2004","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2014.02.013_b0935","doi-asserted-by":"crossref","first-page":"94ra71","DOI":"10.1126\/scitranslmed.3002330","article-title":"A prime-boost strategy using virus-like particles pseudotyped for HCV proteins triggers broadly neutralizing antibodies in macaques","volume":"3","author":"Garrone","year":"2011","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.antiviral.2014.02.013_b0275","doi-asserted-by":"crossref","first-page":"6205","DOI":"10.1073\/pnas.1114927109","article-title":"Human broadly neutralizing antibodies to the envelope glycoprotein complex of hepatitis C virus","volume":"109","author":"Giang","year":"2012","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.antiviral.2014.02.013_b0280","doi-asserted-by":"crossref","first-page":"8400","DOI":"10.1128\/JVI.79.13.8400-8409.2005","article-title":"Role of N-linked glycans in the functions of hepatitis C virus envelope glycoproteins","volume":"79","author":"Goffard","year":"2005","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2014.02.013_b0285","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1002\/hep.22673","article-title":"Development and characterisation of hepatitis C virus genotype 1\u20137 cell culture systems: role of CD81 and scavenger receptor class B type I and effect of antiviral drugs","volume":"49","author":"Gottwein","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.antiviral.2014.02.013_b0290","doi-asserted-by":"crossref","first-page":"12020","DOI":"10.1128\/JVI.01569-08","article-title":"Identification of a residue in Hepatitis C virus E2 glycoprotein that determines scavenger receptor BI and CD81 receptor dependency and sensitivity to neutralising antibodies","volume":"82","author":"Grove","year":"2008","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2014.02.013_b0295","doi-asserted-by":"crossref","first-page":"8101","DOI":"10.1128\/JVI.00127-07","article-title":"The neutralising activity of anti-hepatitis C virus antibodies is modulated by specific glycans on the E2 envelope protein","volume":"81","author":"Helle","year":"2007","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2014.02.013_b0300","doi-asserted-by":"crossref","first-page":"11905","DOI":"10.1128\/JVI.01548-10","article-title":"Role of N-linked glycans in the functions of hepatitis C virus envelope proteins incorporated into infectious virions","volume":"84","author":"Helle","year":"2010","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2014.02.013_b0305","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/nature06106","article-title":"Fc receptor but not complement binding is important in antibody protection against HIV","volume":"449","author":"Hessell","year":"2007","journal-title":"Nature"},{"key":"10.1016\/j.antiviral.2014.02.013_b0310","doi-asserted-by":"crossref","first-page":"7271","DOI":"10.1073\/pnas.0832180100","article-title":"Hepatitis C virus glycoproteins mediate pH-dependent cell entry of pseudotyped retroviral particles","volume":"100","author":"Hsu","year":"2003","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.antiviral.2014.02.013_b0315","doi-asserted-by":"crossref","first-page":"11456","DOI":"10.1128\/JVI.00884-09","article-title":"Full-length characterization of hepatitis C virus subtype 3a reveals novel hypervariable regions under positive selection during acute infection","volume":"83","author":"Humphreys","year":"2009","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2014.02.013_b0320","doi-asserted-by":"crossref","first-page":"6995","DOI":"10.1128\/JVI.78.13.6995-7003.2004","article-title":"Immunization with hepatitis C virus-like particles induces humoral and cellular immune responses in nonhuman primates","volume":"78","author":"Jeong","year":"2004","journal-title":"J. Virol."},{"issue":"612\u2013619","key":"10.1016\/j.antiviral.2014.02.013_b0325","first-page":"e611","article-title":"Emerging therapeutic targets for hepatitis C virus infection","volume":"11","author":"Jesudian","year":"2013","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"10.1016\/j.antiviral.2014.02.013_b0330","doi-asserted-by":"crossref","first-page":"16269","DOI":"10.1073\/pnas.0705522104","article-title":"Human combinatorial libraries yield rare antibodies that broadly neutralize hepatitis C virus","volume":"104","author":"Johansson","year":"2007","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.antiviral.2014.02.013_b0335","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1038\/nrmicro1819","article-title":"The challenges of eliciting neutralizing antibodies to HIV-1 and to influenza virus","volume":"6","author":"Karlsson Hedestam","year":"2008","journal-title":"Nat. Rev. Microbiol."},{"key":"10.1016\/j.antiviral.2014.02.013_b0345","doi-asserted-by":"crossref","first-page":"3923","DOI":"10.1128\/JVI.67.7.3923-3930.1993","article-title":"Humoral immune response to hypervariable region 1 of the putative envelope glycoprotein (gp70) of hepatitis C virus","volume":"67","author":"Kato","year":"1993","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2014.02.013_b0340","doi-asserted-by":"crossref","first-page":"4776","DOI":"10.1128\/JVI.68.8.4776-4784.1994","article-title":"Genetic drift in hypervariable region 1 of the viral genome in persistent hepatitis C virus infection","volume":"68","author":"Kato","year":"1994","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2014.02.013_b0900","doi-asserted-by":"crossref","first-page":"9224","DOI":"10.1128\/JVI.78.17.9224-9232.2004","article-title":"Hepatitis C virus E2 has three immunogenic domains containing conformational epitopes with distinct properties and biological functions","volume":"78","author":"Keck","year":"2004","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2014.02.013_b0350","doi-asserted-by":"crossref","first-page":"13199","DOI":"10.1128\/JVI.79.21.13199-13208.2005","article-title":"Analysis of a highly flexible conformational immunogenic domain a in hepatitis C virus E2","volume":"79","author":"Keck","year":"2005","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2014.02.013_b0360","doi-asserted-by":"crossref","first-page":"6061","DOI":"10.1128\/JVI.02475-07","article-title":"Definition of a conserved immunodominant domain on hepatitis C virus E2 glycoprotein by neutralizing human monoclonal antibodies","volume":"82","author":"Keck","year":"2008","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2014.02.013_b0370","doi-asserted-by":"crossref","first-page":"e1002653","DOI":"10.1371\/journal.ppat.1002653","article-title":"Human monoclonal antibodies to a novel cluster of conformational epitopes on HCV E2 with resistance to neutralization escape in a genotype 2a isolate","volume":"8","author":"Keck","year":"2012","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.antiviral.2014.02.013_b0355","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1128\/JVI.01941-12","article-title":"Cooperativity in virus neutralization by human monoclonal antibodies to two adjacent regions located at the amino terminus of hepatitis C virus E2 glycoprotein","volume":"87","author":"Keck","year":"2013","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2014.02.013_b0375","doi-asserted-by":"crossref","first-page":"5858","DOI":"10.1128\/JVI.00174-13","article-title":"Hepatitis C virus suppresses C9 complement synthesis and impairs membrane attack complex function","volume":"87","author":"Kim","year":"2013","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2014.02.013_b0385","doi-asserted-by":"crossref","first-page":"13085","DOI":"10.1128\/JVI.01939-12","article-title":"Structure of hepatitis C virus envelope glycoprotein E2 antigenic site 412 to 423 in complex with antibody AP33","volume":"86","author":"Kong","year":"2012","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2014.02.013_b0390","doi-asserted-by":"crossref","first-page":"9499","DOI":"10.1073\/pnas.1202924109","article-title":"Structural basis of hepatitis C virus neutralization by broadly neutralizing antibody HCV1","volume":"109","author":"Kong","year":"2012","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.antiviral.2014.02.013_b0380","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1126\/science.1243876","article-title":"Hepatitis C virus E2 envelope glycoprotein core structure","volume":"342","author":"Kong","year":"2013","journal-title":"Science"},{"key":"10.1016\/j.antiviral.2014.02.013_b0395","doi-asserted-by":"crossref","first-page":"e1003364","DOI":"10.1371\/journal.ppat.1003364","article-title":"Structural basis of HCV neutralization by human monoclonal antibodies resistant to viral neutralization escape","volume":"9","author":"Krey","year":"2013","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.antiviral.2014.02.013_b0400","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1128\/JVI.78.3.1575-1581.2004","article-title":"Cross-genotype immunity to hepatitis C virus","volume":"78","author":"Lanford","year":"2004","journal-title":"J. Virol."},{"issue":"1","key":"10.1016\/j.antiviral.2014.02.013_b0940","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1002\/emmm.201303131","article-title":"Emerging therapies for the treatment of hepatitis C","volume":"6","author":"Lange","year":"2014","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.antiviral.2014.02.013_b0410","doi-asserted-by":"crossref","first-page":"8752","DOI":"10.1128\/JVI.02642-06","article-title":"Characterisation of fusion determinants points to the involvement of three discrete regions of both E1 and E2 glycoproteins in the membrane fusion process of hepatitis C virus","volume":"81","author":"Lavillette","year":"2007","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2014.02.013_b0420","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/nm1698","article-title":"Broadly neutralizing antibodies protect against hepatitis C virus quasispecies challenge","volume":"14","author":"Law","year":"2008","journal-title":"Nat. Med."},{"key":"10.1016\/j.antiviral.2014.02.013_b0415","doi-asserted-by":"crossref","first-page":"e59776","DOI":"10.1371\/journal.pone.0059776","article-title":"A hepatitis C virus (HCV) vaccine comprising envelope glycoproteins gpE1\/gpE2 derived from a single isolate elicits broad cross-genotype neutralizing antibodies in humans","volume":"8","author":"Law","year":"2013","journal-title":"PLoS ONE"},{"key":"10.1016\/j.antiviral.2014.02.013_b0425","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1053\/jhep.2001.26523","article-title":"Hepatitis C virus-like particles induce virus-specific humoral and cellular immune responses in mice","volume":"34","author":"Lechmann","year":"2001","journal-title":"Hepatology"},{"key":"10.1016\/j.antiviral.2014.02.013_b0430","doi-asserted-by":"crossref","first-page":"3080","DOI":"10.1016\/j.vaccine.2004.02.002","article-title":"A candidate vaccine based on the hepatitis C E1 protein: tolerability and immunogenicity in healthy volunteers","volume":"22","author":"Leroux-Roels","year":"2004","journal-title":"Vaccine"},{"key":"10.1016\/j.antiviral.2014.02.013_b0435","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1038\/nm1624","article-title":"Broad HIV-1 neutralization mediated by CD4-binding site antibodies","volume":"13","author":"Li","year":"2007","journal-title":"Nat. Med."},{"key":"10.1016\/j.antiviral.2014.02.013_b0440","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1128\/JVI.01992-08","article-title":"Analysis of neutralization specificities in polyclonal sera derived from human immunodeficiency virus type 1-infected individuals","volume":"83","author":"Li","year":"2009","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2014.02.013_b0445","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1126\/science.1114016","article-title":"Complete replication of hepatitis C virus in cell culture","volume":"309","author":"Lindenbach","year":"2005","journal-title":"Science"},{"key":"10.1016\/j.antiviral.2014.02.013_b0450","doi-asserted-by":"crossref","first-page":"5067","DOI":"10.1128\/JVI.02265-09","article-title":"Acceleration of hepatitis C virus envelope evolution in humans is consistent with progressive humoral immune selection during the transition from acute to chronic infection","volume":"84","author":"Liu","year":"2010","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2014.02.013_b0455","doi-asserted-by":"crossref","first-page":"10149","DOI":"10.1073\/pnas.0403519101","article-title":"Neutralizing antibody response during acute and chronic hepatitis C virus infection","volume":"101","author":"Logvinoff","year":"2004","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.antiviral.2014.02.013_b0460","doi-asserted-by":"crossref","first-page":"6711","DOI":"10.1128\/JVI.02582-07","article-title":"Hepatitis C virus (HCV)-induced immunoglobulin hypermutation reduces the affinity and neutralizing activities of antibodies against HCV envelope protein","volume":"82","author":"Machida","year":"2008","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2014.02.013_b0465","doi-asserted-by":"crossref","first-page":"213","DOI":"10.3389\/fmicb.2013.00212","article-title":"Hepatitis C virus infection and related liver disease: the quest for the best animal model","volume":"4","author":"Mailly","year":"2013","journal-title":"Front Microbiol."},{"key":"10.1016\/j.antiviral.2014.02.013_b0475","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1128\/JVI.06577-11","article-title":"Hepatitis C virus proteins inhibit C3 complement production","volume":"86","author":"Mazumdar","year":"2012","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2014.02.013_b0470","doi-asserted-by":"crossref","first-page":"7902","DOI":"10.1128\/JVI.00917-13","article-title":"Hepatitis C virus infection upregulates CD55 expression on the hepatocyte surface and promotes association with virus particles","volume":"87","author":"Mazumdar","year":"2013","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2014.02.013_b0480","doi-asserted-by":"crossref","first-page":"11571","DOI":"10.1128\/JVI.01717-06","article-title":"Hepatitis C virus entry requires a critical postinternalization step and delivery to early endosomes via clathrin-coated vesicles","volume":"80","author":"Meertens","year":"2006","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2014.02.013_b0485","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1016\/S0140-6736(02)08435-0","article-title":"Protection against persistence of hepatitis C","volume":"359","author":"Mehta","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.antiviral.2014.02.013_b0490","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1038\/90968","article-title":"Hepatitis C virus replication in mice chimeric human livers","volume":"7","author":"Mercer","year":"2001","journal-title":"Nat. Med."},{"key":"10.1016\/j.antiviral.2014.02.013_b0495","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1002\/rmv.723","article-title":"Hepatitis C virus entry: beyond receptors","volume":"22","author":"Meredith","year":"2012","journal-title":"Rev. Med. Virol."},{"key":"10.1016\/j.antiviral.2014.02.013_b0500","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1002\/hep.24171","article-title":"In vivo evaluation of the cross-genotype neutralizing activity of polyclonal antibodies against hepatitis C virus","volume":"53","author":"Meuleman","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.antiviral.2014.02.013_b0505","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1128\/JVI.01872-07","article-title":"Isolation and characterization of broadly neutralizing human monoclonal antibodies to the E1 glycoprotein of hepatitis C virus","volume":"82","author":"Meunier","year":"2008","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2014.02.013_b0515","doi-asserted-by":"crossref","first-page":"2150","DOI":"10.1128\/jvi.76.5.2150-2158.2002","article-title":"Complement-mediated enhancement of antibody function for neutralization of pseudotype virus containing hepatitis C virus E2 chimeric glycoprotein","volume":"76","author":"Meyer","year":"2002","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2014.02.013_b0510","doi-asserted-by":"crossref","first-page":"2140","DOI":"10.1128\/JVI.01867-07","article-title":"Antibody-dependent enhancement of hepatitis C virus infection","volume":"82","author":"Meyer","year":"2008","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2014.02.013_b0520","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/S0166-3542(01)00180-2","article-title":"Hypervariable region 1 of hepatitis C virus: immunological decoy or biologically relevant domain?","volume":"52","author":"Mondelli","year":"2001","journal-title":"Antiviral Res."},{"key":"10.1016\/j.antiviral.2014.02.013_b0525","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1128\/JVI.68.1.469-484.1994","article-title":"Probing the structure of the human immunodeficiency virus surface glycoprotein gp120 with a panel of monoclonal antibodies","volume":"68","author":"Moore","year":"1994","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2014.02.013_b0530","doi-asserted-by":"crossref","first-page":"e1002895","DOI":"10.1371\/journal.ppat.1002895","article-title":"Human monoclonal antibody HCV1 effectively prevents and treats HCV infection in chimpanzees","volume":"8","author":"Morin","year":"2012","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.antiviral.2014.02.013_b0535","doi-asserted-by":"crossref","first-page":"8360","DOI":"10.1128\/JVI.00443-10","article-title":"Virus cell-to-cell transmission","volume":"84","author":"Mothes","year":"2010","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2014.02.013_b0540","doi-asserted-by":"crossref","first-page":"6753","DOI":"10.1073\/pnas.1131929100","article-title":"Immunization with hepatitis C virus-like particles protects mice from recombinant hepatitis C virus-vaccinia infection","volume":"100","author":"Murata","year":"2003","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.antiviral.2014.02.013_b0545","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.jhep.2004.12.018","article-title":"Serum antibodies against the hepatitis C virus E2 protein mediate antibody-dependent cellular cytotoxicity (ADCC)","volume":"42","author":"Nattermann","year":"2005","journal-title":"J. Hepatol."},{"key":"10.1016\/j.antiviral.2014.02.013_b0550","first-page":"243","article-title":"Adaptive immune responses in hepatitis C virus infection","volume":"369","author":"Neumann-Haefelin","year":"2013","journal-title":"Curr. Top. Microbiol. Immunol."},{"key":"10.1016\/j.antiviral.2014.02.013_b0905","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1053\/jhep.2003.50474","article-title":"A pilot study of therapeutic vaccination with envelope protein E1 in 35 patients with chronic hepatitis C","volume":"38","author":"Nevens","year":"2003","journal-title":"Hepatology"},{"key":"10.1016\/j.antiviral.2014.02.013_b0560","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1002\/(SICI)1096-9071(199906)58:2<132::AID-JMV6>3.0.CO;2-V","article-title":"Decreased diversity of hepatitis C virus quasispecies during bone marrow transplantation","volume":"58","author":"Ni","year":"1999","journal-title":"J. Med. Virol."},{"key":"10.1016\/j.antiviral.2014.02.013_b0945","doi-asserted-by":"crossref","DOI":"10.1002\/hep.27013","article-title":"Clearance of hepatitis C infection is associated with early appearance of broad neutralizing antibody responses","author":"Osburn","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.antiviral.2014.02.013_b0570","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1099\/0022-1317-82-8-1877","article-title":"Functional analysis of hepatitis C virus E2 glycoproteins and virus-like particles reveals structural dissimilarities between different forms of E2","volume":"82","author":"Owsianka","year":"2001","journal-title":"J. Gen. Virol."},{"key":"10.1016\/j.antiviral.2014.02.013_b0575","doi-asserted-by":"crossref","first-page":"11095","DOI":"10.1128\/JVI.79.17.11095-11104.2005","article-title":"Monoclonal antibody AP33 defines a broadly neutralizing epitope on the hepatitis C virus E2 envelope glycoprotein","volume":"79","author":"Owsianka","year":"2005","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2014.02.013_b0585","doi-asserted-by":"crossref","first-page":"8695","DOI":"10.1128\/JVI.00271-06","article-title":"Identification of conserved residues in the E2 envelope glycoprotein of the hepatitis C virus that are critical for CD81 binding","volume":"80","author":"Owsianka","year":"2006","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2014.02.013_b0580","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1099\/vir.0.83386-0","article-title":"Broadly neutralising human monoclonal antibodies to the hepatitis C virus E2 glycoprotein","volume":"89","author":"Owsianka","year":"2008","journal-title":"J. Gen. Virol."},{"key":"10.1016\/j.antiviral.2014.02.013_b0590","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/j.molmed.2003.09.001","article-title":"Immunofocusing: antigen engineering to promote the induction of HIV-neutralizing antibodies","volume":"9","author":"Pantophlet","year":"2003","journal-title":"Trends Mol. Med."},{"key":"10.1016\/j.antiviral.2014.02.013_b0600","doi-asserted-by":"crossref","first-page":"5889","DOI":"10.1128\/JVI.77.10.5889-5901.2003","article-title":"Hyperglycosylated mutants of human immunodeficiency virus (HIV) type 1 monomeric gp120 as novel antigens for HIV vaccine design","volume":"77","author":"Pantophlet","year":"2003","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2014.02.013_b0910","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1128\/JVI.77.1.642-658.2003","article-title":"Fine mapping of the interaction of neutralizing and nonneutralizing monoclonal antibodies with the CD4 binding site of human immunodeficiency virus type 1 gp120","volume":"77","author":"Pantophlet","year":"2003","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2014.02.013_b0605","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1016\/j.jmb.2013.02.025","article-title":"Glycan shifting on hepatitis C virus (HCV) E2 glycoprotein is a mechanism for escape from broadly neutralizing antibodies","volume":"425","author":"Pantua","year":"2013","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.antiviral.2014.02.013_b0950","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1002\/hep.26524","article-title":"Neutralization resistance of hepatitis C virus can be overcome by recombinant human monoclonal antibodies","volume":"58","author":"Pedersen","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.antiviral.2014.02.013_b0615","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1128\/JVI.01986-07","article-title":"Identification of a broadly cross-reacting and neutralizing human monoclonal antibody directed against the hepatitis C virus E2 protein","volume":"82","author":"Perotti","year":"2008","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2014.02.013_b0620","doi-asserted-by":"crossref","first-page":"6025","DOI":"10.1073\/pnas.0607026104","article-title":"Rapid induction of virus-neutralising antibodies and viral clearance in a single-source outbreak of hepatitis C","volume":"104","author":"Pestka","year":"2007","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.antiviral.2014.02.013_b0625","doi-asserted-by":"crossref","first-page":"7408","DOI":"10.1073\/pnas.0504877103","article-title":"Construction and characterization of infectious intragenotypic and intergenotypic hepatitis C virus chimeras","volume":"103","author":"Pietschmann","year":"2006","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.antiviral.2014.02.013_b0630","doi-asserted-by":"crossref","first-page":"12923","DOI":"10.1128\/JVI.02052-12","article-title":"Toward a hepatitis C virus vaccine: the structural basis of hepatitis C virus neutralization by AP33, a broadly neutralizing antibody","volume":"86","author":"Potter","year":"2012","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2014.02.013_b0635","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1128\/JVI.01594-10","article-title":"Hypervariable region 1 differentially impacts viability of hepatitis C virus strains of genotypes 1 to 6 and impairs virus neutralisation","volume":"85","author":"Prentoe","year":"2011","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2014.02.013_b0640","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1016\/j.vaccine.2003.09.010","article-title":"Immunization of chimpanzees with an envelope protein-based vaccine enhances specific humoral and cellular immune responses that delay hepatitis C virus infection","volume":"22","author":"Puig","year":"2004","journal-title":"Vaccine"},{"key":"10.1016\/j.antiviral.2014.02.013_b0645","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1053\/jhep.2003.50000","article-title":"Hepatitis C virus-like particles combined with novel adjuvant systems enhance virus-specific immune responses","volume":"37","author":"Qiao","year":"2003","journal-title":"Hepatology"},{"key":"10.1016\/j.antiviral.2014.02.013_b0650","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1093\/infdis\/jir835","article-title":"Spontaneous clearance of chronic hepatitis C virus infection is associated with appearance of neutralizing antibodies and reversal of T-cell exhaustion","volume":"205","author":"Raghuraman","year":"2012","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.antiviral.2014.02.013_b0655","doi-asserted-by":"crossref","first-page":"2938","DOI":"10.1128\/JVI.73.4.2938-2946.1999","article-title":"Acute hepatitis C virus structural gene sequences as predictors of persistent viremia: hypervariable region 1 as a decoy","volume":"73","author":"Ray","year":"1999","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2014.02.013_b0660","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1038\/nm.3251","article-title":"Pathogenesis of chronic viral hepatitis: differential roles of T cells and NK cells","volume":"19","author":"Rehermann","year":"2013","journal-title":"Nat. Med."},{"key":"10.1016\/j.antiviral.2014.02.013_b0665","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1073\/pnas.93.5.1759","article-title":"A quantitative test to estimate neutralising antibodies to the hepatitis C virus: Cytofluorimetric assessment of envelope glycoprotein 2 binding to target cells","volume":"93","author":"Rosa","year":"1996","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.antiviral.2014.02.013_b0670","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/1743-422X-5-46","article-title":"Dissecting the role of putative CD81 binding regions of E2 in mediating HCV entry: putative CD81 binding region 1 is not involved in CD81 binding","volume":"5","author":"Rothwangl","year":"2008","journal-title":"Virol. J."},{"key":"10.1016\/j.antiviral.2014.02.013_b0675","doi-asserted-by":"crossref","first-page":"7005","DOI":"10.1128\/JVI.00586-11","article-title":"Neutralizing monoclonal antibodies against hepatitis C virus E2 protein bind discontinuous epitopes and inhibit infection at a postattachment step","volume":"85","author":"Sabo","year":"2011","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2014.02.013_b0680","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1126\/science.1061692","article-title":"Crystal structure of a neutralizing human IgG against HIV-1: A template for vaccine design","volume":"293","author":"Saphire","year":"2001","journal-title":"Science"},{"key":"10.1016\/j.antiviral.2014.02.013_b0685","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S0022-2836(02)00244-9","article-title":"Contrasting IgG structures reveal extreme asymmetry and flexibility","volume":"319","author":"Saphire","year":"2002","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.antiviral.2014.02.013_b0690","doi-asserted-by":"crossref","first-page":"5017","DOI":"10.1093\/emboj\/cdf529","article-title":"The human scavenger receptor class B type I is a novel candidate receptor for the hepatitis C virus","volume":"21","author":"Scarselli","year":"2002","journal-title":"Embo J."},{"key":"10.1016\/j.antiviral.2014.02.013_b0695","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1038\/nature07930","article-title":"Broad diversity of neutralizing antibodies isolated from memory B cells in HIV-infected individuals","volume":"458","author":"Scheid","year":"2009","journal-title":"Nature"},{"key":"10.1016\/j.antiviral.2014.02.013_b0700","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1002\/lt.20876","article-title":"Monoclonal antibody HCV-AbXTL68 in patients undergoing liver transplantation for HCV: Results of a phase 2 randomized study","volume":"12","author":"Schiano","year":"2006","journal-title":"Liver Transpl."},{"key":"10.1016\/j.antiviral.2014.02.013_b0705","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1128\/JVI.68.3.1494-1500.1994","article-title":"Neutralizing antibodies against hepatitis C virus and the emergence of neutralization escape mutant viruses","volume":"68","author":"Shimizu","year":"1994","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2014.02.013_b0710","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/nsmb.1566","article-title":"Structural and functional bases for broad-spectrum neutralisation of avian and human influenza A viruses","volume":"16","author":"Shui","year":"2009","journal-title":"Nat. Struct. Mol. Biol."},{"key":"10.1016\/j.antiviral.2014.02.013_b0715","doi-asserted-by":"crossref","first-page":"3173","DOI":"10.1099\/vir.0.80401-0","article-title":"Genetic diversity and evolution of hepatitis C virus \u2013 15years on","volume":"85","author":"Simmonds","year":"2004","journal-title":"J. Gen. Virol."},{"key":"10.1016\/j.antiviral.2014.02.013_b0720","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1038\/nprot.2009.3","article-title":"Rapid generation of fully human monoclonal antibodies specific to a vaccinating antigen","volume":"4","author":"Smith","year":"2009","journal-title":"Nat. Protocols"},{"key":"10.1016\/j.antiviral.2014.02.013_b0730","doi-asserted-by":"crossref","first-page":"7773","DOI":"10.1016\/j.vaccine.2007.08.053","article-title":"Hepatitis C virus envelope glycoprotein immunization of rodents elicits cross-reactive neutralizing antibodies","volume":"25","author":"Stamataki","year":"2007","journal-title":"Vaccine"},{"key":"10.1016\/j.antiviral.2014.02.013_b0725","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1093\/infdis\/jir399","article-title":"Immunization of human volunteers with hepatitis C virus envelope glycoproteins elicits antibodies that cross-neutralize heterologous virus strains","volume":"204","author":"Stamataki","year":"2011","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.antiviral.2014.02.013_b0735","doi-asserted-by":"crossref","first-page":"2134","DOI":"10.1128\/JVI.77.3.2134-2146.2003","article-title":"Establishment of B-cell lymphoma cell lines persistently infected with hepatitis C virus in vivo and in vitro: the apoptotic effects of virus infection","volume":"77","author":"Sung","year":"2003","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2014.02.013_b0750","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1002\/hep.21088","article-title":"Characterization of the hepatitis C virus E2 epitope defined by the broadly neutralizing monoclonal antibody AP33","volume":"43","author":"Tarr","year":"2006","journal-title":"Hepatology"},{"key":"10.1016\/j.antiviral.2014.02.013_b0745","doi-asserted-by":"crossref","first-page":"2991","DOI":"10.1099\/vir.0.83065-0","article-title":"Determination of the human antibody response to the epitope defined by the hepatitis C virus neutralising monoclonal antibody AP33","volume":"88","author":"Tarr","year":"2007","journal-title":"J. Gen. Virol."},{"key":"10.1016\/j.antiviral.2014.02.013_b0755","doi-asserted-by":"crossref","first-page":"4246","DOI":"10.1128\/JVI.01332-10","article-title":"Hepatitis C patient-derived glycoproteins exhibit marked differences in susceptibility to serum neutralizing antibodies: genetic subtype defines antigenic but not neutralization serotype","volume":"85","author":"Tarr","year":"2011","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2014.02.013_b0760","doi-asserted-by":"crossref","first-page":"2739","DOI":"10.1128\/JVI.06492-11","article-title":"Naturally occurring antibodies that recognize linear epitopes in the amino terminus of the hepatitis C virus E2 protein confer noninterfering, additive neutralization","volume":"86","author":"Tarr","year":"2012","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2014.02.013_b0740","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1002\/hep.26430","article-title":"An alpaca nanobody inhibits hepatitis C virus entry and cell-to-cell transmission","volume":"58","author":"Tarr","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.antiviral.2014.02.013_b0765","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.jim.2007.09.017","article-title":"Efficient generation of monoclonal antibodies from single human B cells by single cell RT-PCR and expression vector cloning","volume":"329","author":"Tiller","year":"2008","journal-title":"J. Immunol. Meth."},{"key":"10.1016\/j.antiviral.2014.02.013_b0915","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1002\/hep.21959","article-title":"Hepatitis C virus cell\u2013cell transmission in hepatoma cells in the presence of neutralizing antibodies","volume":"47","author":"Timpe","year":"2007","journal-title":"Hepatology"},{"key":"10.1016\/j.antiviral.2014.02.013_b0775","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1099\/0022-1317-76-7-1871","article-title":"Sequence analysis of hepatitis C virus genotypes 1\u20135 reveals multiple novel subtypes in the Benelux countries","volume":"76","author":"van Doorn","year":"1995","journal-title":"J. Gen. Virol."},{"key":"10.1016\/j.antiviral.2014.02.013_b0780","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.1002\/hep.22244","article-title":"Polyclonal immunoglobulins from a chronic hepatitis C virus patient protect human liver-chimeric mice from infection with a homologous hepatitis C virus strain","volume":"47","author":"Vanwolleghem","year":"2008","journal-title":"Hepatology"},{"key":"10.1016\/j.antiviral.2014.02.013_b0785","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1093\/infdis\/jir423","article-title":"Clearance of genotype 1b hepatitis C virus in chimpanzees in the presence of vaccine-induced E1-neutralising antibodies","volume":"204","author":"Verstrepen","year":"2011","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.antiviral.2014.02.013_b0790","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1053\/j.gastro.2006.12.008","article-title":"Hepatitis C virus continuously escapes from neutralizing antibody and T-cell responses during chronic infection in vivo","volume":"132","author":"von Hahn","year":"2007","journal-title":"Gastroenterology"},{"key":"10.1016\/j.antiviral.2014.02.013_b0795","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1038\/nm1268","article-title":"Production of infectious hepatitis C virus in tissue culture from a cloned viral genome","volume":"11","author":"Wakita","year":"2005","journal-title":"Nat. Med."},{"key":"10.1016\/j.antiviral.2014.02.013_b0800","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.coi.2010.02.012","article-title":"Rational antibody-based HIV-1 vaccine design: current approaches and future directions","volume":"22","author":"Walker","year":"2010","journal-title":"Cur. Opin. Immunol."},{"key":"10.1016\/j.antiviral.2014.02.013_b0805","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1126\/science.1178746","article-title":"Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target","volume":"326","author":"Walker","year":"2009","journal-title":"Science"},{"key":"10.1016\/j.antiviral.2014.02.013_b0810","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/nature01470","article-title":"Antibody neutralisation and escape by HIV-1","volume":"422","author":"Wei","year":"2003","journal-title":"Nature"},{"key":"10.1016\/j.antiviral.2014.02.013_b0820","doi-asserted-by":"crossref","first-page":"3468","DOI":"10.1073\/pnas.89.8.3468","article-title":"Evidence for immune selection of hepatitis C virus (HCV) putative envelope glycoprotein variants: potential role in chronic HCV infections","volume":"89","author":"Weiner","year":"1992","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.antiviral.2014.02.013_b0815","doi-asserted-by":"crossref","first-page":"7142","DOI":"10.1128\/JVI.75.15.7142-7148.2001","article-title":"Intrahepatic genetic inoculation of hepatitis C virus RNA confers cross-protective immunity","volume":"75","author":"Weiner","year":"2001","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2014.02.013_b0825","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1099\/vir.0.006700-0","article-title":"CD81 is dispensable for hepatitis C virus cell-to-cell transmission in hepatoma cells","volume":"90","author":"Witteveldt","year":"2009","journal-title":"J. Gen. Virol."},{"key":"10.1016\/j.antiviral.2014.02.013_b0830","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1126\/science.1187659","article-title":"Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1","volume":"329","author":"Wu","year":"2010","journal-title":"Science"},{"key":"10.1016\/j.antiviral.2014.02.013_b0835","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1002\/hep.20934","article-title":"Sustained E2 antibody response correlates with reduced peak viremia after hepatitis C virus infection in the chimpanzee","volume":"42","author":"Youn","year":"2005","journal-title":"Hepatology"},{"key":"10.1016\/j.antiviral.2014.02.013_b0840","doi-asserted-by":"crossref","first-page":"7705","DOI":"10.1073\/pnas.0402458101","article-title":"Neutralizing antibodies to hepatitis C virus (HCV) in immune globulins derived from anti-HCV-positive plasma","volume":"101","author":"Yu","year":"2004","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.antiviral.2014.02.013_b0845","first-page":"87","article-title":"Hepatitis C virus entry","volume":"369","author":"Zeisel","year":"2013","journal-title":"Curr. Top. Microbiol. Immunol."},{"key":"10.1016\/j.antiviral.2014.02.013_b0920","doi-asserted-by":"crossref","first-page":"8449","DOI":"10.1073\/pnas.0703039104","article-title":"Hepatitis C virus epitope specific neutralizing antibodies in Igs prepared from human plasma","volume":"104","author":"Zhang","year":"2007","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.antiviral.2014.02.013_b0925","doi-asserted-by":"crossref","first-page":"7537","DOI":"10.1073\/pnas.0902749106","article-title":"Depletion of interfering antibodies in chronic hepatitis C patients and vaccinated chimpanzees reveals broad cross-genotype neutralizing activity","volume":"106","author":"Zhang","year":"2009","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.antiviral.2014.02.013_b0860","doi-asserted-by":"crossref","first-page":"9294","DOI":"10.1073\/pnas.0503596102","article-title":"Robust hepatitis C virus infection in vitro","volume":"102","author":"Zhong","year":"2005","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.antiviral.2014.02.013_b0865","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1002\/hep.510250530","article-title":"Early antibody response against hypervariable region 1 is associated with acute self-limiting infections of hepatitis C virus","volume":"25","author":"Zibert","year":"1997","journal-title":"Hepatology"},{"key":"10.1016\/j.antiviral.2014.02.013_b0870","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1053\/jhep.2001.22175","article-title":"Mimotopes of the hepatitis C virus hypervariable region 1, but not the natural sequences, induce cross-reactive antibody response by genetic immunization","volume":"33","author":"Zucchelli","year":"2001","journal-title":"Hepatology"},{"key":"10.1016\/j.antiviral.2014.02.013_b0875","doi-asserted-by":"crossref","first-page":"5863","DOI":"10.1128\/JVI.77.10.5863-5876.2003","article-title":"Molecular features of the broadly neutralizing immunoglobulin G1 b12 required for recognition of human immunodeficiency virus type 1 gp120","volume":"77","author":"Zwick","year":"2003","journal-title":"J. Virol."}],"container-title":["Antiviral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354214000564?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354214000564?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,8,15]],"date-time":"2020-08-15T15:42:00Z","timestamp":1597506120000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0166354214000564"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,5]]},"references-count":174,"alternative-id":["S0166354214000564"],"URL":"https:\/\/doi.org\/10.1016\/j.antiviral.2014.02.013","relation":{},"ISSN":["0166-3542"],"issn-type":[{"value":"0166-3542","type":"print"}],"subject":[],"published":{"date-parts":[[2014,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The past, present and future of neutralizing antibodies for hepatitis C virus","name":"articletitle","label":"Article Title"},{"value":"Antiviral Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.antiviral.2014.02.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}